Gelucire Based In Situ Gelling Emulsions: A Potential Carrier for Sustained Stomach Specific Delivery of Gastric Irritant Drugs

Table 4

Anti-inflammatory response obtained from Piroxicam containing in situ gelling formulations (E3 and E5) compared to suspension formulation and control using carrageenan induced hind paw oedema method.

Treatment	Dose	Volume of mercury displaced (in mL.)
		1 hr	2 hr	3 hr	4 hr	5 hr	6 hr
Control (normal saline)	1 mL/kg	0.42±0.108	0.44±0.102	0.58±0.0131	0.72±0.0103	0.90±0.0147	0.92±0.0134
Standard (Piroxicam suspension)	1 mg/kg	0.27±0.009^∗; (35.71%)	0.28±0.008^∗; (36.36%)	0.34±0.012^∗; (41.37%)	0.41±0.012^∗; (43.05%)	0.50±0.018^∗; (44.44%)	0.54±0.016^∗; (40.00%)
E3	1 mg/kg	0.29±0.002; (30.95%)	0.29±0.005; (34.09%)	0.28±0.005^∗; (51.71%)	0.30±0.011^∗; (58.33%)	0.34±0.042^∗; (62.22%)	0.40±0.009; (55.55%)
E5	1 mg/kg	0.29±0.002; (30.95%)	0.28±0.009^∗; (36.36%)	0.31±0.005^∗; (46.55%)	0.37±0.005^∗; (48.61%)	0.41±0.009^∗; (54.44%)	0.47 ± 0.01 (48.91%)